May 9, 2002
Researchers at several sites in the U.S. recruited 21 HIV positive subjects for this study which compared the effect of two different boosted protease inhibitor (PI) regimens:
The combinations were taken with two or more other anti-HIV drugs.
The profile of subjects was as follows:
Three subjects left the study for the following reasons:
One subject, who was taking the 400/400-mg regimen had his viral load rise above the 1,000 copy mark during the study.
By the sixth month of the study, more subjects (9) on the 1,000/100 regimen had suppressed their viral load compared to subjects on the 400/400 regimen (6).
Over time, there were trends to lower triglyceride and cholesterol levels in subjects given 1,000/100. CD4+ counts were also higher in that group. As well, the 1,000/100 combination was better tolerated than the combination that included a higher dose of ritonavir. More details about tolerating saquinavir appear in our next CATIE News story: "Invirase vs. Fortovase -- Unexpected Results?"